Florida Biologix - - BioPharm International


Florida Biologix

BioPharm International
Volume 19, Issue 12

Company Description

Florida Biologix is a nonprofit contract manufacturing and testing organization whose primary focus is cGMP compliant production of Phase 1 and 2 clinical trial material on time and at reasonable prices. Our senior cGMP manufacturing, Quality Control and Quality Assurance managers have over 90 years of combined biopharmaceutical manufacturing experience. Our operational model, location, and affiliations help to keep costs low.

Markets Served

We provide a wide range of services to the biopharmaceutical industry, biomedical research institutions, and academia.

Products and Services

Our services include: cell line engineering, cGMP cell banking, upstream and downstream process design, process and assay development, cGMP production of proteins expressed in mammalian cells (including monoclonal antibodies, recombinant proteins, enzymes, vaccines and other biomolecules), purification, aseptic vial filling (including small molecules, nucleic acids and proteins), product testing, and regulatory support. Process development and scale-up of non-GMP material is also available.


Our new, 16,000-sq. ft. validated, multiproduct facility has been designed and built with process and support equipment to provide timely, high-quality, cGMP compliant Phase 1 and Phase 2 contract manufacturing and testing services. The 5,000 sq. ft. process development laboratories, located in a separate building adjacent to the cGMP facility, are equipped with the same state-of-the-art equipment as the manufacturing site.

13702 Innovation Drive
Alachua, FL 32615




blog comments powered by Disqus



Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines
Source: BioPharm International,
Click here